The Myeloma Alphabet Soup Handbook
Thalidomide for the treatment of multiple myeloma

LITTLE ROCK, Ark., Sept. 28, 1998 /PRNewswire/ -- Encouraging new data on thalidomide for the treatment of multiple myeloma, the second most common blood cancer, was presented by Jayesh Mehta, M.D., of the Arkansas Cancer Research Center (ACRC) this weekend at a meeting of the Leukemia Society of America in Washington, D.C.

In a study of 26 patients with end state refractory (non-responsive) multiple myeloma who were treated with thalidomide, the disease ceased to progress in nearly 60% of patients, with some patients experiencing a reduction in tumor growth and 3 patients approaching complete response. Ninety-two percent of the patients in the study had received bone marrow transplants, with close to 70% receiving this treatment at least twice. In all cases, bone marrow transplantation had failed as a therapy. Preliminary data from an expanded study of 125 multiple myeloma patients, are consistent with the findings in the initial study of 26 patients. The side effects of the drug were consistent with those seen in other thalidomide clinical studies. The thalidomide (THALOMID(TM)) used in these studies was provided by Celgene Corporation [Nasdaq:CELG - news] of Warren, New Jersey.

Celgene Corporation
7 Powder Horn Drive
Warren, NJ 07059 USA
1 (888)663-3662

Celgene Announces Plan to Pursue Multiple Myeloma Indication for THALOMIDT (Thalidomide).
Thalidomide STEPS data.
Thalidomide STEPS data.

Subscribing to the Myeloma List | Home Page | Transplants

Last Updated: 02/10/99